학술논문
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFRexon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
Document Type
Article
Author
Wang, Mengzhao; Fan, Yun; Sun, Meili; Wang, Yongsheng; Zhao, Yanqiu; Jin, Bo; Hu, Ying; Han, Zhigang; Song, Xia; Liu, Anwen; Tang, Kejing; Ding, Cuimin; Liang, Li; Wu, Lin; Gao, Junzhen; Wang, Jianghong; Cheng, Ying; Zhou, Jianying; He, Yong; Dong, Xiaorong; Yao, Yu; Yu, Yan; Wang, Huijie; Sun, Si; Huang, Jianan; Fang, Jian; Li, Wen; Wang, Lin; Ren, Xiubao; Zhou, Chengzhi; Hu, Yanping; Zhao, Dahai; Yang, Runxiang; Xu, Fei; Huang, Yijiang; Pan, Yueyin; Cui, Jiuwei; Xu, Yan; Yang, Zhenfan; Shi, Yuankai
Source
The Lancet Respiratory Medicine; March 2024, Vol. 12 Issue: 3 p217-224, 8p
Subject
Language
ISSN
22132600; 22132619
Abstract
Sunvozertinib is an oral, irreversible, and selective tyrosine kinase inhibitor that has a favourable safety profile and encouraging antitumour activity, as shown in phase 1 studies of patients with heavily pretreated non-small cell lung cancer (NSCLC) with EGFRexon 20 insertion mutation (exon20ins). We aimed to assess the antitumour efficacy of sunvozertinib in patients with platinum-pretreated locally advanced or metastatic NSCLC with EGFRexon20ins.